KLRS
Kalaris Therapeutics Inc
NASDAQ · Healthcare · Biotechnology · US
$3.90
−1.02%Next report
Analyst consensus
- Next report date
- Nov 11, 2026
- EPS estimate
- -$0.52
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 11, 2026
- EPS actual
- -$0.48
- EPS estimate
- -$0.49
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 4
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +10.6%
- Revenue beats (12Q)
- —
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 11, 2026